Thalidomide in patients with advanced multiple myeloma

Hematology Journal

Volumn 1, Issue 3, 2000, Pages 186-189

  Yakoub Agha, Ibrahim ^a   Moreau, Philippe ^b   Leyvraz, Serge ^c   Berthou, Christian ^d   Payen, Catherine ^e   Dumontet, Charles ^f   Grosbois, Bernard ^g   Beris, Photis ^h   Duguet, Corinne ⁱ   Attal, Michel ^e   Harousseau, Jean Luc ^b   Facon, Thierry ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d BREST UNIVERSITY HOSPITAL   (France)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h Division d'Hématologie   (Switzerland)

ⁱ Laboratories LAPHAL   (France)

Author keywords

Anti angiogenic; Multiple myeloma; Neutropenia; Response; Thalidomide; Tolerance

Indexed keywords

ANGIOGENESIS INHIBITOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; THALIDOMIDE;

AGRANULOCYTOSIS; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; PATHOLOGY; TIME; TREATMENT OUTCOME;

AGRANULOCYTOSIS; ANGIOGENESIS INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MULTIPLE MYELOMA; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034585033     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200031     Document Type: Article

References (15)

1. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. Journal of Clinical Oncology 10: 334, 1992.
2. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. New England Journal of Medicine 330: 484, 1994.
3. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. New England Journal of Medicine 335: 91, 1996.
4. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93: 55, 1999.
5. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B, Siegel D, Crowley J. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. New England Journal of Medicine 341: 1565, 1999.
6. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the USA 91: 4082, 1994.
7. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Experimental Eye Research 64: 971, 1997.
8. Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minischetti M, Marzullo A, Herken R, Roncali L, Dammacco F. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. British Journal of Cancer 79: 451, 1999.
9. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma. British Journal of Haematology 87: 503, 1994.
10. Vacca A, Di Loreto M, Ribatti D, Di Stefano R, Gadaleta-Caldarola G, Iodice G, Caloro D, Dammacco F. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. American Journal of Hematology 50: 9, 1995.
11. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clinical Immunology and Immunopathology 81: 219, 1996.
12. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. Journal of Experimental Medicine 173: 699, 1991.
13. Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Stirling D, Kaplan G. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Molecular Medicine 2: 506, 1996.
14. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. Journal of Experimental Medicine 187: 1885, 1998.
15. Geitz H, Handt S, Zwingenberger K. Thalidomide selectivity modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31: 213, 1996.